Search research articles
Contact Us
Filters
Showing results (241-250 of 254) with videos related to
Page
of 26
Sort By:
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
April 30, 2023
[Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease after allogeneic hematopoietic cell transplantation successfully treated with triple immunosuppressive therapy]
Yuhei Nakamura, Shunto Kawamura, Shimpei Matsumi, et al.
Transplantation and Cellular Therapy
|
August 29, 2023
Clinical Impact of Pretransplantation Physical Function on Transplantation after Allogeneic Hematopoietic Cell Transplantation in Older Adults
Ayumi Gomyo, Shun-Ichi Kimura, Junko Suzuki, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
September 3, 2017
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology
|
April 14, 2017
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, et al.
Journal of Diabetes Investigation
|
October 9, 2025
Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study)
Munehiro Kitada, Masao Toyoda, Osamu Sekine, et al.
Cardiovascular Diabetology
|
January 5, 2021
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
August 6, 2021
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology
|
July 11, 2020
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology
|
June 22, 2023
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Rheumatology (Oxford, England)
|
November 7, 2023
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study
Koshiro Sonomoto, Shingo Nakayamada, Yoshihisa Fujino, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 254) with videos related to
Sort By:
Page
of 26
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
April 30, 2023
[Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease after allogeneic hematopoietic cell transplantation successfully treated with triple immunosuppressive therapy]
Yuhei Nakamura, Shunto Kawamura, Shimpei Matsumi, et al.
Transplantation and Cellular Therapy
|
August 29, 2023
Clinical Impact of Pretransplantation Physical Function on Transplantation after Allogeneic Hematopoietic Cell Transplantation in Older Adults
Ayumi Gomyo, Shun-Ichi Kimura, Junko Suzuki, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
September 3, 2017
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology
|
April 14, 2017
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, et al.
Journal of Diabetes Investigation
|
October 9, 2025
Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study)
Munehiro Kitada, Masao Toyoda, Osamu Sekine, et al.
Cardiovascular Diabetology
|
January 5, 2021
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
August 6, 2021
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology
|
July 11, 2020
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology
|
June 22, 2023
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Rheumatology (Oxford, England)
|
November 7, 2023
Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study
Koshiro Sonomoto, Shingo Nakayamada, Yoshihisa Fujino, et al.
Page
of 26